Drug profile

The FDA adverse-event record for Glucosamine Hydrochloride Supplement

27 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine Hydrochloride Supplement. See the species affected, top reactions, and outcomes below.

27
adverse-event reports
7.4%
death-coded share
Dog
most-reported species
7
Panting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
27
Total Reports
2
Deaths Reported
7.4%
Death Rate

Active Ingredients

Glucosamine Hydrochloride Supplement

Administration Routes

OralUnknown

Species Affected

Dog 24
Cat 3

Most Affected Breeds

Retriever - Labrador 7
Shepherd Dog - German 4
Domestic Shorthair 3
Spaniel - Cocker American 1
Shepherd Dog - Australian 1
Crossbred Canine/dog 1
Bichon Frise 1
Maltese 1
Terrier - Yorkshire 1
Doberman Pinscher 1

Most Reported Reactions

Panting 7
Vomiting 6
Underdose 4
Lethargy (see also Central nervous system depression in Neurological) 4
Lethargy (see also Central nervous system depression in 'Neurological') 3
Emesis (multiple) 3
Pain NOS 3
Weight loss 2
Fever 2
Other abnormal test result NOS 2
Inappetence 2
Neutrophilia 2

Outcome Breakdown

Outcome Unknown
13 (48.1%)
Recovered/Normal
12 (44.4%)
Euthanized
2 (7.4%)

Glucosamine Hydrochloride Supplement Adverse Event Insights

27 reports name Glucosamine Hydrochloride Supplement; 2 recorded a death outcome (7.4% of reported events, not a population-level mortality rate). Active ingredient: Glucosamine Hydrochloride Supplement. Administration routes: Oral, Unknown.

By species: Dog (24 reports), Cat (3 reports). By breed: Retriever - Labrador (7), Shepherd Dog - German (4), Domestic Shorthair (3).

Leading clinical signs: Panting (7), Vomiting (6), Underdose (4), Lethargy (see also Central nervous system depression in Neurological) (4). Outcome, 27 coded reports: Outcome Unknown leads at 48.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.